第99.1展示文本
personalis報告2024年第二季度財務結果
由生物製藥業務帶動，年度營業收入強勁增長35%，其中生物製藥業務增長117%。
提高2024年全年營業收入指引
加利福尼亞州弗裏蒙特 - 2024年8月7日 - Personalis, Inc.（納斯達克：PSNL），一家在精準腫瘤基因組學領域領先的公司，今天公佈了截至2024年6月30日的第二季度財務業績，並介紹了最近的業務成就。
最近的業務成就
與2023年第二季度相比，2024年第二季度的結果
1
營業收入增長反映出客戶對我們的技術和平台的信心不斷增強。重要的是，我們臨床測試成交量的增長意味着我們可以看到對患者生活的影響。現在，我們的合作伙伴已經提出了令人信服的NeXt Personal臨床證據，我們期待利用這一點來獲取Medicare報銷，並顯著增加我們可以幫助的患者人數。”首席執行官克里斯·霍爾表示：「隨着我們繼續執行我們的Win-in-MRD策略，我們對自己推動廣泛採用患者檢測的能力比以往任何時候都更有信心。」
2024年第三季度和修訂後的全年展望
personalis期望2024年第三季度如下：
personalis預計在2024年整年會有以下表現：
網絡廣播和電話會議信息
personalis將在2024年8月7日週三美國太平洋時間下午2點（東部時間下午5點）收盤後舉行電話會議，討論2024年第二季度的財務業績，以及2024年的計劃。請撥打800-717-1738（國內用戶）或646-307-1865（國際用戶）參與直播。直播網絡研討會可在 https://investors.personalis.com。電話會議結束後不久將提供網絡研討會的回放，並將存檔在公司網站上。
關於Personalis公司。
在personalis，我們通過突破性的個性化測試改變癌症的積極管理。我們的目標是推動癌症管理的新範式，從活檢到患者的一生。我們的高度敏感的檢測結合腫瘤和正常的基因組特徵分析，配合專有算法，提供先進的見解
2
癌症在不斷進化的同時。我們的產品旨在檢測最小殘留疾病（MRD）和早期復發，根據超全面的基因組分析進行靶向治療選擇，並加強藥物開發的生物標誌物策略。Personalis總部位於加利福尼亞弗裏蒙特。要了解更多，請訪問 www.personalis.com並通過LinkedIn和X (推特).
非通用會計準則財務指標
爲了補充我們根據GAAP制定的財務指導，我們提供了截至2024年12月31日全年預期的非GAAP淨損失，其中不包括來自於向Tempus發行的未行使權證所產生的收入和費用。我們排除了與Tempus發行的未行使權證公允價值相關的收入和費用，因爲這些是非現金財務指標，需要根據截至每個報告日期的本公司普通股的當時交易價格進行公允價值重估，因此在預測Tempus權證在未來測量日期的公允價值時存在重大不確定性。基於這個原因，我們沒有提供我們前瞻性的非GAAP淨損失與GAAP淨損失（最直接可比的GAAP財務指標）的調和，依賴於適用法規中規定的「不合理費力」的例外情況。
前瞻性聲明
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that are not historical facts and can generally be identified by terms such as “anticipate,” “estimate,” “expect,” “if,” “may,” “future,” “will” or similar expressions. These statements include statements relating to: Personalis’ third quarter and full year 2024 outlook for revenue, non-GAAP net loss, and cash usage, the attributes, advantages or clinical validity of the NeXT Personal Dx test, broad adoption of the NeXT Personal Dx test for patient testing and the benefits to patients from use of the same, and Personalis’ obtaining Medicare coverage. Such forward-looking statements involve known and unknown risks and uncertainties and other factors that may cause actual results to differ materially from any anticipated results or expectations expressed or implied by such statements, including the risks, uncertainties and other factors that relate to the timing and pace of new orders from customers, including from Natera and the U.S. Department of Veterans Affairs Million Veterans Program; the timing of tissue, blood, and other specimen sample receipts from customers, which can materially impact revenue quarter-over-quarter and year-over-year; Personalis’ ability to demonstrate attributes, advantages or clinical validity of the NeXT Personal Dx test, the rate of adoption of the NeXT Personal Dx test, Personalis’ ability to obtain Medicare coverage and reimbursement, Personalis’ achievement of milestones set forth in the collaboration and co-commercialization agreement with Tempus, the success of Personalis’ clinical sales team and Tempus’ sales and marketing efforts, the expected benefits or success of Personalis’ relationships with research collaborators, the impact of Personalis’ abstract presentations at the American Society of Clinical Oncology medical conference in May, and the adoption and use of the NeXT Personal Dx test by oncologists. These and other potential risks and uncertainties that could cause actual results to differ materially from the results predicted in these forward-looking statements are described under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in Personalis’ Annual Report on Form 10-K for the year ended December 31, 2023, filed with the Securities and Exchange Commission (SEC) on February 28, 2024, as updated by Personalis’ Quarterly Report on Form 10-Q for the quarter ended March 31, 2024, filed with the SEC on May 8, 2024, and Quarterly Report on Form 10-Q for the quarter ended June 30, 2024, being filed with the SEC today. All information provided in this release is as of the date of this press release, and any forward-looking statements contained herein are based on assumptions that we believe to be reasonable as of this date. Undue reliance should not be placed on the forward-looking statements in this press release, which are based on information available to us on the date hereof. Personalis undertakes no duty to update this information unless required by law.
3
Contacts:
Investor Relations Contact:
Caroline Corner
investors@personalis.com
646-277-1279
Media:
pr@personalis.com
4
PERSONALIS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited)
(in thousands, except share and per share data)
|
|
Three Months Ended June 30, |
|
|
Six Months Ended June 30, |
|
||||||||||
|
|
2024 |
|
|
2023 |
|
|
2024 |
|
|
2023 |
|
||||
Revenue |
|
$ |
22,580 |
|
|
$ |
16,699 |
|
|
$ |
42,105 |
|
|
$ |
35,559 |
|
Costs and expenses |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Cost of revenue |
|
|
14,543 |
|
|
|
11,907 |
|
|
|
28,575 |
|
|
|
26,037 |
|
Research and development |
|
|
12,957 |
|
|
|
17,852 |
|
|
|
25,728 |
|
|
|
34,425 |
|
Selling, general and administrative |
|
|
11,973 |
|
|
|
12,134 |
|
|
|
23,575 |
|
|
|
26,231 |
|
Restructuring and other charges |
|
|
— |
|
|
|
152 |
|
|
|
— |
|
|
|
4,037 |
|
Total costs and expenses |
|
|
39,473 |
|
|
|
42,045 |
|
|
|
77,878 |
|
|
|
90,730 |
|
Loss from operations |
|
|
(16,893 |
) |
|
|
(25,346 |
) |
|
|
(35,773 |
) |
|
|
(55,171 |
) |
Interest income |
|
|
1,136 |
|
|
|
1,465 |
|
|
|
2,495 |
|
|
|
2,718 |
|
Interest expense |
|
|
(9 |
) |
|
|
(39 |
) |
|
|
(18 |
) |
|
|
(86 |
) |
Other income (expense), net |
|
|
2,968 |
|
|
|
1 |
|
|
|
7,537 |
|
|
|
(25 |
) |
Loss before income taxes |
|
|
(12,798 |
) |
|
|
(23,919 |
) |
|
|
(25,759 |
) |
|
|
(52,564 |
) |
Provision for income taxes |
|
|
4 |
|
|
|
36 |
|
|
|
11 |
|
|
|
50 |
|
Net loss |
|
$ |
(12,802 |
) |
|
$ |
(23,955 |
) |
|
$ |
(25,770 |
) |
|
$ |
(52,614 |
) |
Net loss per share, basic and diluted |
|
$ |
(0.24 |
) |
|
$ |
(0.50 |
) |
|
$ |
(0.50 |
) |
|
$ |
(1.11 |
) |
Weighted-average shares outstanding, basic and diluted |
|
|
52,394,678 |
|
|
|
47,669,513 |
|
|
|
51,536,632 |
|
|
|
47,204,891 |
|
5
PERSONALIS, INC.
SUPPLEMENTAL REVENUE INFORMATION (unaudited)
(in thousands)
|
|
Three Months Ended June 30, |
|
|
Six Months Ended June 30, |
|
||||||||||
|
|
2024 |
|
|
2023 |
|
|
2024 |
|
|
2023 |
|
||||
Pharma tests and services |
|
$ |
13,197 |
|
|
$ |
6,083 |
|
|
$ |
23,009 |
|
|
$ |
12,416 |
|
Enterprise sales |
|
|
7,958 |
|
|
|
7,386 |
|
|
|
15,930 |
|
|
|
16,844 |
|
Population sequencing |
|
|
1,280 |
|
|
|
3,000 |
|
|
|
2,780 |
|
|
|
6,005 |
|
Other |
|
|
145 |
|
|
|
230 |
|
|
|
386 |
|
|
|
294 |
|
Total revenue |
|
$ |
22,580 |
|
|
$ |
16,699 |
|
|
$ |
42,105 |
|
|
$ |
35,559 |
|
6
PERSONALIS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited)
(in thousands, except share and per share data)
|
|
June 30, 2024 |
|
|
December 31, 2023 |
|
||
Assets |
|
|
|
|
|
|
||
Current assets |
|
|
|
|
|
|
||
Cash and cash equivalents |
|
$ |
47,747 |
|
|
$ |
56,984 |
|
Short-term investments |
|
|
39,225 |
|
|
|
57,195 |
|
Accounts receivable, net |
|
|
12,921 |
|
|
|
17,730 |
|
Inventory and other deferred costs |
|
|
9,164 |
|
|
|
10,474 |
|
Prepaid expenses and other current assets |
|
|
4,046 |
|
|
|
4,361 |
|
Total current assets |
|
|
113,103 |
|
|
|
146,744 |
|
Property and equipment, net |
|
|
52,662 |
|
|
|
57,366 |
|
Operating lease right-of-use assets |
|
|
17,166 |
|
|
|
17,852 |
|
Other long-term assets |
|
|
2,571 |
|
|
|
3,137 |
|
Total assets |
|
$ |
185,502 |
|
|
$ |
225,099 |
|
Liabilities and Stockholders’ Equity |
|
|
|
|
|
|
||
Current liabilities |
|
|
|
|
|
|
||
Accounts payable |
|
$ |
9,936 |
|
|
$ |
14,920 |
|
Accrued and other current liabilities |
|
|
19,248 |
|
|
|
23,941 |
|
Contract liabilities |
|
|
4,174 |
|
|
|
3,288 |
|
Short-term warrant liability |
|
|
775 |
|
|
|
5,085 |
|
Total current liabilities |
|
|
34,133 |
|
|
|
47,234 |
|
Long-term operating lease liabilities |
|
|
36,524 |
|
|
|
38,321 |
|
Long-term warrant liability |
|
|
1,513 |
|
|
|
4,942 |
|
Other long-term liabilities |
|
|
1,060 |
|
|
|
5,161 |
|
Total liabilities |
|
|
73,230 |
|
|
|
95,658 |
|
Commitments and contingencies |
|
|
|
|
|
|
||
Stockholders’ equity |
|
|
|
|
|
|
||
Preferred stock, $0.0001 par value — 10,000,000 shares authorized; none issued |
|
|
— |
|
|
|
— |
|
Common stock, $0.0001 par value — 200,000,000 shares authorized; 53,052,847 and 50,480,694 shares issued and outstanding, respectively |
|
|
5 |
|
|
|
5 |
|
Additional paid-in capital |
|
|
606,863 |
|
|
|
598,364 |
|
Accumulated other comprehensive loss |
|
|
(120 |
) |
|
|
(222 |
) |
Accumulated deficit |
|
|
(494,476 |
) |
|
|
(468,706 |
) |
Total stockholders’ equity |
|
|
112,272 |
|
|
|
129,441 |
|
Total liabilities and stockholders’ equity |
|
$ |
185,502 |
|
|
$ |
225,099 |
|
7